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A small number of testicular germ cell tumours are refractory to current chemotherapy regimens. DNA topoisomerase I is the
target for several new drugs and a potential candidate treatment for chemorefractory germ cell tumours. DNA topoisomerase IIa
is the target for etoposide, which is currently used regularly in germ cell tumour treatment. The expression of DNA topoisomerase
I and IIa weretherefore assessed immunohistochemically in a rangeof testicular tumours, especially those with persistent malignant
elements on retroperitoneal lymph node dissection. Pre-chemotherapy orchidectomy specimens were matched with post-
chemotherapy retroperitoneal lymph node dissections to examine changes in expression. There was considerable variation in the
expression of topoisomerase I in different tumour types. Both yolk sac tumours and teratoma, mature showed universal
expression of topoisomerase I, while 38% of seminomas and 30% of embryonal carcinomas were positive. Strong topoisomerase
IIa expression was found in embryonal carcinoma. There was a negative correlation between topoisomerase I and IIa expression
(P=0.004) and downregulation of topoisomerase IIa after chemotherapy (P=0.02). Topoisomerase I expression appears to
increase in those cases with residual teratoma, mature, but is largely unchanged in those cases remaining as embryonal carcinoma.
These results suggest that topoisomerase I inhibitors may be useful in chemorefractory germ cell tumours, especially yolk sac
tumours and where there are unresectable residual teratoma, mature deposits.
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The treatment of metastatic non-seminomatous germ cell tumours
consists of orchidectomy plus ‘BEP’ combination chemotherapy –
bleomycin, etoposide and cisplatin. First line chemotherapy gives a
5-year survival rate for patients with metastatic germ cell tumours
(GCT) of over 80% (International Germ Cell Cancer Collaborative
Group, 1997). Despite the high success rate of this treatment, the
BEP regimen has serious side effects and there is a 1% incidence
of drug fatality. Residual masses may remain and it has become
common practise to excise these surgically (Einhorn et al, 1981).
Histology from these masses has a complex range of appearances
and the complete resection of embryonal carcinoma (EC) or other
malignant elements is important (Fox et al, 1993; Fizazi et al, 1999;
Albers et al, 2000). Residual teratoma, mature (TM) is also resected
where possible because of the danger of dedifferentiation, or trans-
formation to a variety of other tumour types (Hull et al, 1994;
Little et al, 1994; Michael et al, 2000).
Controversy exists regarding the use of further adjuvant
chemotherapy (salvage chemotherapy) in these patients, as most
are cured by surgery alone (Tait et al, 1984; Williams et al,
1997). It is clear however that effective salvage chemotherapy does
exist for those patients who do relapse (Loehrer et al, 1998;
Shamash et al, 1999). The omission of chemotherapy in these
patients would be considered as undertreatment. Patients whose
germ cell tumours recur at greater than 2 years from original resec-
tion (late recurrences) have a generally poor chemo-responsiveness
to current therapies (Michael et al, 2000). There remains therefore,
a small subgroup of patients who are resistant to current modes of
therapy.
The human DNA topoisomerases are members of the gyrase
family of enzymes. They are nuclear enzymes, which transiently
break and unwind DNA at times when the cell requires access to
the genetic material for replication and transcription (Wang,
1996). They are also involved in many cellular activities including
chromosome condensation and recombination, DNA repair and
segregation during mitosis (Husain et al, 1994).
Genes coding for the topoisomerase (topo) enzymes are highly
conserved across species. Topo I is targeted by the camptothecins
(Takimoto et al, 1998) and has been shown to be elevated in many
human malignancies (Husain et al, 1994; Mcleod et al, 1994). Topo
II isoenzymes are the targets for the epipodophyllotoxins and for
DNA intercalators such as the anthracyclines (Sano and Shuhin,
1995).
Typically, these drugs do not inhibit the free enzyme but stabi-
lise the covalently bound topoisomerase-DNA complex (Rubin,
2000), thus preventing the rejoining of the broken DNA fragments.
They act not so much as inhibitors, but as ‘poisons’. The sensitivity
of cells to the topoisomerase-targeted drugs is therefore related to
the levels of topoisomerase in the nucleus, making immunohisto-
chemical assessment a putative measure of likely cell sensitivity
to chemotherapy (Madden and Champoux, 1992). The camptothe-
cins have been investigated recently as possible agents for testicular
GCT’s (Sano and Shuhin, 1995; Miki et al, 1997; Coleman et al,
2000).
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www.bjcancer.comThe aims of this project are to identify the presence of the topo I
and IIa in different testicular tumour types, especially those resistant
to current therapeutic regimens, to aid the identiﬁcation of potential
targets for salvage chemotherapy using the topoisomerase inhibitors.
MATERIALS AND METHODS
Cases were identiﬁed from the Barts and The London NHS Trust
medical oncology database. These included 14 matched cases of
orchidectomy plus retroperitoneal lymph node dissection from
patients who had residual tumour following their initial course
of therapy. Some of the matched pre-chemotherapy orchidectomy
tumour blocks were requested from other hospitals, which were
largely those participating in the East Anglia germ cell tumour
group. Thirteen cases were also identiﬁed of retroperitoneal lymph
node dissection following an initial course of therapy but where the
original orchidectomy was not available. Nearly all these cases had
residual malignant or immature elements and therefore represented
a selection of the cases which had not responded to conventional
therapy. Twelve orchidectomies were also identiﬁed from patients
who had been diagnosed with seminomas for comparison with
the teratoma group. All cases were anonymised.
The cases were all reviewed and the different elements within
them identiﬁed assisted by immunochemistry where appropriate.
Embryonal carcinoma was identiﬁed by the immunohistochemical
presence of CD30 in the primary tumours, or by histological appear-
ances in the post-chemotherapy cases (Berney et al, 2001a). 3 mm
formalin ﬁxed, parafﬁn embedded tissue sections were cut from
the selected tissue blocks. Antigen retrieval was used for all of the
antibodies used. The antibodies used were topo I (mouse monoclo-
nal antibody Clone ID6, Novacastra), topo IIa (mouse monoclonal
antibody Code 3F6, Novacastra), topo IIa (rabbit polyclonal anti-
body, Novacastra) and Ki-67 (rabbit polyclonal Code AO47,
Dako). Ki-67 was included to compare the proliferation index with
the topo II enzymes. Normal tonsil was used for a positive control
and a negative control was included for each case.
Protocols for immunochemistry were followed according to
those used for the topoisomerases in previous studies (Monnin et
al, 1999). All the antibodies used show nuclear staining. Cytoplas-
mic staining was disregarded. Protocols for immunohistochemical
detection of topo I followed a previous study (Holden et al,
1997) and graded the expression of the enzyme in the tissue
samples on a subjective scale of 0 to 3+. Staining 2+ or 3+ was
counted as positive, and anything less as negative. The expression
of the topo II enzyme and Ki-67 was assessed by quantitatively
calculating the number of positive cells out of 500 (expressed as
a percentage). Fifty cells were counted in 10 random ﬁelds within
the tumour area. Five hundred cells were counted within each case.
RESULTS
The expression of topo I in the different tumour types is repre-
sented in Table 1. Tonsillar tissue, used as a positive control,
showed strong staining in lymphoid follicles and in squamous
epithelium. Macrophages, which are seen in all normal follicles
ingesting apoptotic debris, were noted to be negative (Figure 1).
Background ﬁbrous tissue was also negative for all the tested anti-
bodies. Positive internal controls included lymphocytes especially
in the seminomas. Negative internal controls were areas of normal
spermatogenesis in the testes where the spermatids, as expected,
were seen to be negative (Figure 2).
Universal strong expression was shown in TM (Figure 3) and
also in yolk sac (Figure 4). Pre chemotherapy, both EC and semi-
noma showed similar percentages of cases to be positive (ﬁve out
of 12 and ﬁve out of 13 respectively). After chemotherapy however,
only two out of 11 cases of EC showed nuclear positivity. Promi-
nent cytoplasmic staining was noted in the EC group in many cases
but this was not counted as positive. Seminomas were chosen as
the control group to attempt to determine statistically which of
the groups of tumour may respond well to anti-topo I therapy.
TM was universally positive for topo I and is signiﬁcantly different
from the seminoma group (P50.003, Fisher’s exact test). Yolk sac
(YS) was also signiﬁcantly different from seminoma (P50.018).
The changes in expression of topo I after chemotherapy showed
that both increases and decreases in expression occurred. Increases
occurred in cases which differentiated from EC to TM or YS. Cases
with persistent EC either became negative or remained unchanged.
Twenty-eight of the total number of specimens were stained
with both the polyclonal and monoclonal version of the topo
IIa antibody. The tonsil used for control purposes showed very
strong nuclear staining in follicles and in basal epithelium. Similar
to topo I, spermatids were negative where present in primary
orchidectomy cases. The correlation between both antibodies
against topo II was strong (R=0.908; P50.001) after testing 28
of the cases and therefore the remaining cases were tested with
the monoclonal antibody only. The frequency distribution of this
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Figure 1 Control showing strong positivity for topo I in a lymphoid
follicle. Note the negative macrophages with larger irregular nuclei.
Black bar=50 mm.
Table 1 Topoisomerase I and IIa positivity in selected tumour types
Primary Primary Post- Yolk Post
seminoma EC chemotherapy EC sac chemotherapy TM
Topo I
Positive 5 5 2 6 10
Negative 8 7 9 0 0
Topo II
Positive 6 8 5 1 0
Negative 7 4 6 5 10
EC=Embryonal carcinoma, TM=Teratoma, mature.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(6), 624–629antibody was bimodal with 24% used as the cut off between posi-
tive and negative cases (Figure 5). Topo II positivity is compared
with the tumour type in Table 1. The highest topo II index was
seen in cases of EC. Lower rates were seen in seminomas (Figure
6), YS and TM. The TM group showed a signiﬁcantly lower topo
IIa index than seminoma (P=0.019, Fisher’s exact test). Topo I
was also compared with topo II expression (Table 2). There was
a strong inverse correlation between the two proteins (P=0.004,
Fisher’s exact test), however a few tumours showed dual high
expression. Ki-67 showed a positive correlation (r=0.69,
P50.01) with topo II expression (Figure 7), demonstrating that
topo IIa expression is a reasonable measure of proliferating cells.
This has been reported in many previous studies (Davidson et al,
2000; Gupta et al, 2000; Morisaki et al, 2000). There was a signif-
icant reduction (P=0.02, Wilcoxan signed ranks matched pairs
test) in topo II positivity after chemotherapy (Figure 8). It was
noted that the pre-treatment samples were normally distributed
(P=0.188, Anderson-Darling test) while the post treatment
samples were not normally distributed (P50.001, Anderson-
Darling test).
DISCUSSION
DNA Topoisomerase I has been identiﬁed as a molecular target
for the plant alkaloid Camptothecin (Husain et al, 1994; Holden
et al, 1997). This is a derivative of Camptotheca acuminata
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Figure 4 Topo I positivity in a yolk sac tumour. Black bar=50 mm.
Figure 3 Strong topo I positivity in a mature teratoma after chemother-
apy, showing positive chondrocytes and glandular epithelium (top right).
Black bar=50 mm.
Figure 2 Cross-section of a normal seminiferous tubule showing
strongly topo I positive spermatocytes and negative spermatids. Black
bar=15 mm.
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Figure 5 Frequency distribution of topoisomerase IIa index.
Figure 6 Positive nuclear staining for topo II in a seminoma. Note the
strongly positive tripolar mitosis. Black bar=30 mm.
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British Journal of Cancer (2002) 87(6), 624–629 ã 2002 Cancer Research UK(Chinese willow) and shows antitumour activity in human solid
tumours including colorectal, prostate and ovarian cancers. These
drugs act by preventing the resealing of the DNA, and thus tran-
scription is unable to continue. The greater the amount of topo
I a cell has, the more cleavable complexes can be formed within
it, and hence, the cell is more drug sensitive (Holden et al,
1997). It has also been shown that there is good correlation
between the immunohistochemical level of topo I in tissue and
catalytic activity (Coleman et al, 2000). The increased expression
of topo I in tumour tissue may therefore provide a target for
selective therapeutic cytotoxicity in other human cancers. This
is supported by experimental evidence that Camptothecin-resis-
tant tumour cell lines express reduced levels of topo I (Husain
et al, 1994).
Topo I has been measured previously in a variety of other
malignancies and normal tissues, by immunochemistry, RT–
PCR, enzymatic activity and Western blotting. Increased expression
has been shown in ovarian epithelial carcinomas (Codegoni et al,
1998), transitional cell carcinomas of the bladder (Monnin et al,
1999), renal cell carcinomas (Gupta et al, 2000) and lung tumours
(Mirski et al, 2000). Normal topo I levels were seen in the back-
ground tissue of the above studies.
Two isoforms of the topo II enzyme exist – alpha and beta. The
alpha form is the more important. Its activity is highest during S,
G2 and M phases, with low activity during G1 phase. Both the
monoclonal and polyclonal antibodies to topo IIa used in this
study are speciﬁc for the carboxy-terminal of the molecule and
do not cross-react with topo IIb. The activity of topo IIa can be
up-regulated by the inhibition of topo I (Whitacre et al, 1997).
This has an important clinical relevance since, it is conceivable that
topo I inhibitors could be used to up-regulate topo IIa, thus
making cells more sensitive to topo IIa inhibitors. The results
supported an inverse relationship between topo I and topo IIa
(Table 2).
Many drugs inhibit topo IIa by stabilising the topo II-DNA clea-
vable complex (Houlbrook et al, 1995). Some topo IIa inhibitors
are able to intercalate part of their structure between adjacent
DNA bases, e.g. the anthracyclines and anthracene diones which
are effectively trapped in the nucleus at a high concentration. They
can therefore be administered by a single injection, and will be held
in the cell until S phase when topo II activity peaks and they are
able exert their effect. Other inhibitors, such as etoposide, do not
intercalate and require prolonged administration to increase the
chance of exposure to cells during S phase. Seminomas are well
known to be sensitive to etoposide (Mencel et al, 1994). Evidence
suggests that the cellular level of topo IIa determines the degree of
drug toxicity (Houlbrook et al, 1995). The decreased expression of
topo IIa has been shown to be associated with resistance to
chemotherapy (Koshiyama et al, 2001).
The ﬁnding of most interest was the tumour speciﬁcity of high
topo I expression. Both the TM group, and the yolk sac group
show universal strong expression making them potential candidates
for treatment with topotecan or irinotecan. The presence of high
levels of topo I in TM was unexpected. TM comprises only a small
minority of primary GCT’s, and these are treated by surgery
followed by surveillance. However, after the administration of
chemotherapy, the tumours frequently change their morphology
and approximately 40% of cases show pure TM. These are routi-
nely resected, though in cases with widespread metastases these
foci may be inaccessible to surgery. Despite their quiescent nature,
there is a risk of progression and presentation as late recurrences
(Michael et al, 2000). Thus, if topo I has been upregulated in these
foci, administration of an inhibitor may represent an adjunct or
alternative to surgical removal in speciﬁc cases. Yolk sac tumour
is more aggressive than TM but showed similar strong positive
expression for topo I. Therefore, in those cases resistant to standard
regimens, administration of a topo I inhibitor may be efﬁcacious.
Coleman et al (2000) investigated the topo I and II expression in
seminomas alone. Our results for expression of topo I and II are
similar to theirs (6 out of 20 seminomas being positive for topo
I in their study and 5 out of 13 in our study). The strong cytoplas-
mic positivity seen in many cases of EC has been disregarded.
However, it has been noted that expression of a cytoplasmic
mutant variant of topo IIa has been reported in a lung cancer cell
line that was etoposide resistant (Mirski and Cole, 1995). This
supports the decision to disregard all cytoplasmic staining.
The primary embryonal carcinomas were the group with the
highest expression of topo IIa (8 out of 12) while TM had the
lowest (0 out of 10). On comparison with the seminoma group,
TM had a signiﬁcantly lower topo IIa (P=0.019). The signiﬁcant
reduction in topo IIa after chemotherapy in matched cases is
explained by the transformation to TM from EC. The lack of a
normal distribution in the post-chemotherapy cases highlights the
variable response to primary chemotherapy.
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Table 2 Comparison of topoisomerase I and II
Topoisomerase II Topoisomerase II
Positive Negative
Topoisomerase I Positive 6 23
Topoisomerase I Negative 15 9
There is a negative correlation between topo I and II (P=0.004, Fisher’s exact test).
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Figure 7 Comparison of the percentage of Ki-67 positive cells with the
percentage of topoisomerase IIa positive cells (r=0.69, P50.01).
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Figure 8 Comparison of topoisomerase II expression in matched
samples before and after chemotherapy (P=0.02, Wilcoxan signed
ranks matched pairs test).
Topoisomerase in germ cell tumours
DM Berney et al
627
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(6), 624–629Ki-67 has been shown to be a useful marker in assesment of
likelihood of relapse in metastatic germ cell tumours (Berney et
al, 2001b). Comparison of Ki-67 with topo IIa shows a good corre-
lation, indicating that topo IIa levels are a fair indicator of
proliferating cells. Topo I is thought to be most active in cells with
a high S phase fraction as DNA replication forks collide with the
stabilised topo I-DNA complex (D’Arpa et al, 1990). However,
non-replicating cells have been shown to be sensitive to topo I,
possibly because of collisions with transcriptional complexes
(Morris and Geller, 1996; Wu and Liu, 1997). Therefore in resis-
tant cases, topo I inhibitors may be of great utility.
It should be recognised that upsteam and downstream variables
may affect the sensitivity of the tumour to these drugs. The trans-
port proteins Mrp2/Moat (Allen et al, 1999) and Brcp/Mxr1 (Koike
et al, 1997) have been implicated in the efﬂux of topo I inhibitors
and etoposide is a substrate for the cellular efﬂux protein Mdr1
(Rubin, 2000). However, clinical trials on tumours resistant to
conventional chemotherapy and in cases not amenable to surgery
are necessary to evaluate the response of these speciﬁc types of
tumour to the camptothecins.
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